Brief: Everest Medicines Says U.S. FDA Granted Full Approval Of Trodelvy To Gilead Sciences
09/04/2021 02:23
April 9 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES - U.S. FDA HAS GRANTED FULL APPROVAL OF
TRODELVY TO GILEAD SCIENCES, INC. A LICENSING PARTNER OF CO
* EVEREST MEDICINES - APPROVAL IS FOR TREATMENT OF
PREVIOUSLY
TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC
TRIPLE-NEGATIVE BREAST CANCER
Source text for Eikon: ID:nHKS9hSXCQ
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region